Using semaglutide to manage high blood sugar after kidney transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of semaglutide, a glucose-lowering medication, in managing hyperglycemia in patients who have recently undergone renal transplantation. The study compares semaglutide to a placebo, both administered alongside standard insulin treatment, to determine if semaglutide can effectively regulate plasma glucose levels without the common side effects associated with insulin. Additionally, the trial aims to assess the impact of semaglutide on renal graft function, weight management, and overall safety in this patient population. The study is designed to provide insights into the potential benefits of semaglutide for improving post-transplant outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent obtained before any trial-related procedures are performed
2. Male or female; age: 18-80 years
3. Diagnosis of post-transplant hyperglycaemia 10 to 40 days after transplantation: Fasting plasma glucose ≥ 7.0 mmol/L or an oral glucose tolerance test with at plasma glucose ≥ 11.1 mmol/L or Pre-transplant type 2 diabetes: Receiving glucose-lowring treatment prior to kidney transplantation
4. An eGFR \> 15 ml/min/1.73 m2 10 to 40 days after renal transplantation
5. Subject must be willing and able to comply with trial protocol

Exclusion Criteria:

1. Type 1 diabetes
2. Dialysis
3. High risk immunological transplantation (not including ABO-incompatible or re-transplantation)
4. Early graft rejection (all rejections verified by biopsy, except borderline rejections. Study initiations can begin 5 days after last dose of rejection treatment with methylprednisolone)
5. Chronic pancreatitis/previous acute pancreatitis
6. Known or suspected hypersensitivity to trial or related products
7. Use of DPP-4 inhibitors within five days prior to screening
8. Use of GLP-1RA within 10 days prior to screening
9. Malignancy (except basal cell carcinoma)
10. Inflammatory bowel disease
11. Previous bowel resection
12. Cardiac disease defined as decompensated heart failure (New York Heart Association class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last six months
13. Any acute condition or exacerbation of chronic condition that would in the investigator's opinion interfere with the initial trial visit schedule and procedures.
14. Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant, or are not using adequate contraceptive methods
15. Impaired liver function (plasma ALAT \> two times upper reference levels)
16. Elevated amylase (plasma amylase \> two times upper reference levels)
17. Untreated proliferative diabetic retinopathy, untreated diabetic macular edema or active conditions of this type that are not under therapeutic control according
18. Any condition that clinically significantly impairs the observation of the fundus or anterior chamber

Where it's running

• Department og Nephrology and Endocrinology, Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Tobias Bomholt, MD, PhD
• Email: Tobias.bomholt@regionh.dk
• Phone: +4535457952

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Miniature breath sensors to detect hypo- and hyperglycemia in young people with diabetes

  A small breath-sensor device will try to see if specific breath compounds can signal low or high blood sugar in youths with diabetes.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07696273

• Breath sensor for detecting hypo- and hyperglycemia in teens with type 1 diabetes

  This test checks whether a breath-based VOC sensor can spot low or high blood sugar in 12–19-year-olds with type 1 diabetes who use a Dexcom CGM.

  Recruiting Indiana University · Indianapolis, Indiana · NCT06893341

• Monitoring glucose levels in critically ill patients

  This study looks at how often critically ill patients in the ICU experience low blood sugar and how using continuous glucose monitors can help improve their care.

  Recruiting Universidad Europea de Madrid · Madrid · NCT06234787

• Improving diabetes management in hospitals with a decision support tool

  This study is testing a new electronic tool that helps doctors manage blood sugar levels in hospitalized patients with diabetes to see if it improves their care and reduces costs.

  Recruiting at 2 sites Milton S. Hershey Medical Center · Hershey, Pennsylvania and 1 other locations · NCT05447806

• Maltodextrin vs Sugar Water for Pre-Surgery Carbohydrate Loading in Older Adults

  This study tests whether a maltodextrin drink before surgery leaves less fluid in the stomach than sugar water for adults 60 and older undergoing leg surgery with spinal or epidural anesthesia.

  Recruiting Udayana University · Denpasar, Bali · NCT07872683

• Managing pasireotide-related high blood sugar in acromegaly with a ketogenic diet

  This study tests whether a very-low carbohydrate ketogenic diet can help lower HbA1c and fasting glucose in adults with acromegaly who develop high blood sugar while taking pasireotide.

  Recruiting Leiden University Medical Center · Leiden, South Holland · NCT07866846

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.